Concert Pharmaceuticals' once-a-day candidate begins trials; Study supportive of Genentech's injectable eye drug;

> Concert Pharmaceuticals announced it has begun Phase I study of its candidate for cystic fibrosis, which it hopes will enable once-a-day dosing. More

> A study in the Journal of the American Medical Association found that injection of Genentech's eye drug Lucentis performed noninferiorly to a laser-based procedure treating diabetic retinopathy. More

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.